Sept 28 U.S health regulators on Friday approved
Abbott Laboratories Inc's blockbuster rheumatoid
arthritis drug Humira for the treatment of moderate to severe
ulcerative colitis in adults.
The U.S. Food and Drug Administration approved Humira to
control the chronic inflammatory condition once
immunosuppressant medicines, such as corticosteroids, have
Humira, by far Abbott's biggest product with annual sales of
about $8 billion and still growing, is already approved to treat
a number of inflammatory diseases. In addition to rheumatoid
arthritis, the medicine is approved for psoriatic arthritis,
ankylosing spondylitis, Crohn's disease, plaque psoriasis and
juvenile idiopathic arthritis.